User profiles for Philip R. Dormitzer
 | Philip R DormitzerGSK Verified email at gsk.com Cited by 38563 |
[HTML][HTML] Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine
…, DB Tresnan, S Mather, PR Dormitzer… - New England journal …, 2020 - Mass Medical Soc
Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and
the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in …
the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in …
[HTML][HTML] Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months
…, DB Tresnan, S Mather, PR Dormitzer… - … England Journal of …, 2021 - Mass Medical Soc
Background BNT162b2 is a lipid nanoparticle–formulated, nucleoside-modified RNA vaccine
encoding a prefusion-stabilized, membrane-anchored severe acute respiratory syndrome …
encoding a prefusion-stabilized, membrane-anchored severe acute respiratory syndrome …
[HTML][HTML] COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses
…, W Kalina, CA Kyratsous, D Cooper, PR Dormitzer… - Nature, 2020 - nature.com
An effective vaccine is needed to halt the spread of the severe acute respiratory syndrome
coronavirus-2 (SARS-CoV-2) pandemic. Recently, we reported safety, tolerability and …
coronavirus-2 (SARS-CoV-2) pandemic. Recently, we reported safety, tolerability and …
[HTML][HTML] Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates
…, KE Lyke, V Raabe, PR Dormitzer… - … England Journal of …, 2020 - Mass Medical Soc
Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections
and the resulting disease, coronavirus disease 2019 (Covid-19), have spread to millions of …
and the resulting disease, coronavirus disease 2019 (Covid-19), have spread to millions of …
[HTML][HTML] Evaluation of the BNT162b2 Covid-19 vaccine in children 5 to 11 years of age
…, D Cooper, Ö Türeci, PR Dormitzer… - … England Journal of …, 2022 - Mass Medical Soc
Background Safe, effective vaccines against coronavirus disease 2019 (Covid-19) are urgently
needed in children younger than 12 years of age. Methods A phase 1, dose-finding study …
needed in children younger than 12 years of age. Methods A phase 1, dose-finding study …
[HTML][HTML] Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents
…, DB Tresnan, S Mather, PR Dormitzer… - … England Journal of …, 2021 - Mass Medical Soc
Background Until very recently, vaccines against severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) had not been authorized for emergency use in persons younger than …
2 (SARS-CoV-2) had not been authorized for emergency use in persons younger than …
[HTML][HTML] BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
…, M Cutler, D Cooper, CA Kyratsous, PR Dormitzer… - Nature, 2021 - nature.com
BNT162b2, a nucleoside-modified mRNA formulated in lipid nanoparticles that encodes the
SARS-CoV-2 spike glycoprotein (S) stabilized in its prefusion conformation, has …
SARS-CoV-2 spike glycoprotein (S) stabilized in its prefusion conformation, has …
[HTML][HTML] Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults
…, EE Walsh, R Frenck, AR Falsey, PR Dormitzer… - Nature, 2020 - nature.com
In March 2020, the World Health Organization (WHO) declared coronavirus disease 2019 (COVID-19),
which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-…
which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-…
[HTML][HTML] SARS-CoV-2 neutralization with BNT162b2 vaccine dose 3
…, KU Jansen, U Şahin, PR Dormitzer… - … England Journal of …, 2021 - Mass Medical Soc
Immune Response to a Third Dose of BNT162b2 A third dose of the BNT162b2 vaccine was
administered to 23 volunteers 8 to 9 months after the second dose, and the immune …
administered to 23 volunteers 8 to 9 months after the second dose, and the immune …
[HTML][HTML] Neutralizing activity of BNT162b2-elicited serum
…, KU Jansen, X Xie, PR Dormitzer… - … England Journal of …, 2021 - Mass Medical Soc
Variant SARS-CoV-2 and BNT162b2 Vaccine How well do serum samples obtained from
persons injected with the BNT162b2 vaccine neutralize the P.1, B.1.1.7, and B.1.135 lineages …
persons injected with the BNT162b2 vaccine neutralize the P.1, B.1.1.7, and B.1.135 lineages …